 |
|
The Autoantibody Response to Ro/SSA in Cutaneous Lupus Erythematosus
Lela A. Lee, MD;
Charles M. Roberts, PhD;
Mark Barton Frank, PhD;
Victoria R. McCubbin;
Morris Reichlin, MD
Arch Dermatol. 1994;130(10):1262-1268.
Abstract
| |
Background and Design
Seventeen patients with subacute cutaneous lupus erythematosus (SCLE) were compared with 15 patients with discoid lupus erythematosus (DLE) to evaluate the relationship of 60- and 52-kd Ro/SSA autoantibodies to the clinical diagnosis and to evaluate assays for anti-Ro/SSA.
Results
All serum samples from patients with SCLE had precipitating anti-Ro/SSA antibodies in immunodiffusion, and all had high titer anti—60-kd Ro/SSA in enzyme-linked immunosorbent assay. Immunoblotting was inadequately sensitive for detecting anti—60-kd Ro/SSA. Fifteen patients with SCLE had anti—52-kd Ro/SSA (11 high titer, four low titer). Only one of the 15 patients with DLE had precipitating, high-titer anti-Ro/SSA. Nine other patients with DLE had low-titer anti—60-kd Ro/SSA, and four had low-titer anti— 52-kd Ro/SSA. Low-titer anti-Ro/SSA did not confer an increased risk for photosensitivity in the DLE group.
Conclusions
High-titer, precipitating antibodies to Ro/SSA are typical of SCLE and unusual in DLE. Lowtiter, nonprecipitating antibodies to Ro/SSA are common in DLE and could be an indication of pathogenic factors shared with SCLE. However, low titers of antiRo/SSA do not confer a significant risk for SCLE skin lesions. For the purpose of clinical evaluation of skin disease, immunodiffusion assays for anti-Ro/SSA are cost-effective and informative.
(Arch Dermatol. 1994;130:1262-1268)
Author Affiliations
From the Departments of Dermatology (Dr Lee), Medicine (Drs Lee and Reichlin), and Microbiology/Immunology (Drs Lee, Frank, and Reichlin), University of Oklahoma Health Sciences Center; the Arthritis/Immunology Program (Drs Lee, Frank, and Reichlin and Ms McCubbin), Oklahoma Medical Research Foundation; the Department of Veterans Affairs Medical Center (Drs Lee and Reichlin); the Oklahoma Center for Molecular Medicine (Drs Lee and Frank); and the Department of Chemistry, Oklahoma School of Science and Mathematics (Dr Roberts), Oklahoma City.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Drug-induced lupus: an update on its dermatologic aspects
Marzano et al.
Lupus 2009;18:935-940.
ABSTRACT
Clinical and laboratory characteristics of Finnish lupus erythematosus patients with cutaneous manifestations
Koskenmies et al.
Lupus 2008;17:337-347.
ABSTRACT
Fine specificity of the Ro/SSA autoantibody response in relation to serological and clinical findings in 96 patients with self-reported cutaneous symptoms induced by the sun
Popovic et al.
Lupus 2007;16:10-17.
ABSTRACT
SS-A/Ro52, an Autoantigen Involved in CD28-Mediated IL-2 Production
Ishii et al.
J. Immunol. 2003;170:3653-3661.
ABSTRACT
| FULL TEXT
The Diagnosis of Photosensitivity
Roelandts
Arch Dermatol 2000;136:1152-1157.
ABSTRACT
| FULL TEXT
Systemic lupus erythematosus: clinical expression and anti-Ro/SS--A response in patients with and without lesions of subacute cutaneous lupus erythematosus
Lopez-Longo et al.
Lupus 1997;6:32-39.
ABSTRACT
The lexicon of cutaneous lupus erythematosus-A review and personal perspective on the nomenclature and classification of the cutaneous manifestations of lupus erythematosus
Sontheimer
Lupus 1997;6:84-95.
Pathology, immunopathology, and immunohistochemistry in cutaneous lupus erythematosus
David-Bajar and Davis
Lupus 1997;6:145-157.
Cutaneous diseases in adults associated with Anti-Ro/SS-A autoantibody production
McCauliffe
Lupus 1997;6:158-166.
The Relationship Between Discoid and Systemic Lupus Erythematosus
Provost
Arch Dermatol 1994;130:1308-1310.
ABSTRACT
|
